BR9916328A - Inibidores de transferase de farnesila - Google Patents

Inibidores de transferase de farnesila

Info

Publication number
BR9916328A
BR9916328A BR9916328-4A BR9916328A BR9916328A BR 9916328 A BR9916328 A BR 9916328A BR 9916328 A BR9916328 A BR 9916328A BR 9916328 A BR9916328 A BR 9916328A
Authority
BR
Brazil
Prior art keywords
transferase inhibitors
farnesyl transferase
compounds
disclosed
farnesyl
Prior art date
Application number
BR9916328-4A
Other languages
English (en)
Inventor
Timothy Guzi
Dinanath F Rane
Alan K Mallams
Alan B Cooper
Ronald J Doll
Viyyoor M Girijavallabhan
Arthur G Taveras
Corey Strickland
Joseph M Kelly
Jianping Chao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9916328A publication Critical patent/BR9916328A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES DE TRANSFERASE DE FARNESILA"<D>. Revelados são compostos da fórmula (1.0), em que R^ 8^ representa uma porção cíclica à qual está ligada um grupo imidazolilalquila; R^ 9^ representa um grupo carbamato, uréia, amido ou sulfonamida; e os substituintes restantes são como definidos aqui. Também revelado é um método de tratamento de câncer e um método de inibição de transferase de proteína de farnesila usando-se os compostos revelados.
BR9916328-4A 1998-12-18 1999-12-16 Inibidores de transferase de farnesila BR9916328A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21656098A 1998-12-18 1998-12-18
PCT/US1999/027938 WO2000037458A1 (en) 1998-12-18 1999-12-16 Farnesyl protein transferase inhibitors

Publications (1)

Publication Number Publication Date
BR9916328A true BR9916328A (pt) 2001-10-02

Family

ID=22807539

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916328-4A BR9916328A (pt) 1998-12-18 1999-12-16 Inibidores de transferase de farnesila

Country Status (24)

Country Link
EP (1) EP1140904B1 (pt)
JP (1) JP2002533335A (pt)
KR (1) KR20010081115A (pt)
CN (1) CN1285588C (pt)
AR (1) AR021716A1 (pt)
AT (1) ATE293622T1 (pt)
AU (1) AU2347900A (pt)
BR (1) BR9916328A (pt)
CA (1) CA2354774C (pt)
CO (1) CO5160344A1 (pt)
CZ (1) CZ20011900A3 (pt)
DE (1) DE69924876T2 (pt)
ES (1) ES2237963T3 (pt)
HK (1) HK1036279A1 (pt)
HU (1) HUP0203054A3 (pt)
ID (1) ID29065A (pt)
IL (1) IL143409A0 (pt)
NO (1) NO20012960L (pt)
PE (1) PE20001516A1 (pt)
PL (1) PL348294A1 (pt)
SK (1) SK7582001A3 (pt)
TR (1) TR200101754T2 (pt)
WO (1) WO2000037458A1 (pt)
ZA (1) ZA200104236B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361663B2 (en) 1999-11-10 2008-04-22 Aventis Pharmaceuticals Inc. N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
AU2155001A (en) * 1999-11-10 2001-06-06 Aventis Pharma Deutschland Gmbh N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
WO2002056884A2 (en) * 2001-01-22 2002-07-25 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
CA2438264A1 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
ES2312845T3 (es) * 2002-12-17 2009-03-01 Schering Corporation Inhibidores de la deshidrogenasa de 17 beta-hidroxiesteroides de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
WO2006065828A2 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
CA2591123A1 (en) 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CN101400656A (zh) * 2006-01-19 2009-04-01 先灵公司 作为法呢基蛋白转移酶抑制剂的哌嗪衍生物
AU2009249306B8 (en) * 2008-05-22 2013-07-25 Merck Canada Inc. Process for the preparation of an orexin receptor antagonist
HU231150B1 (hu) 2017-03-13 2021-03-29 Richter Gedeon Nyrt Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására
TW202220992A (zh) 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种（R）-1-Boc-3-羟甲基哌嗪的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
GB9420172D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
WO1998057960A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase

Also Published As

Publication number Publication date
CO5160344A1 (es) 2002-05-30
ES2237963T3 (es) 2005-08-01
AR021716A1 (es) 2002-07-31
IL143409A0 (en) 2002-04-21
SK7582001A3 (en) 2002-03-05
EP1140904B1 (en) 2005-04-20
WO2000037458A1 (en) 2000-06-29
NO20012960D0 (no) 2001-06-15
DE69924876T2 (de) 2006-03-02
ATE293622T1 (de) 2005-05-15
ZA200104236B (en) 2002-08-23
DE69924876D1 (de) 2005-05-25
HK1036279A1 (en) 2001-12-28
PL348294A1 (en) 2002-05-20
CA2354774C (en) 2009-05-26
CN1352642A (zh) 2002-06-05
ID29065A (id) 2001-07-26
HUP0203054A3 (en) 2004-01-28
NO20012960L (no) 2001-08-15
JP2002533335A (ja) 2002-10-08
EP1140904A1 (en) 2001-10-10
TR200101754T2 (tr) 2002-05-21
CZ20011900A3 (cs) 2002-02-13
KR20010081115A (ko) 2001-08-27
CA2354774A1 (en) 2000-06-29
AU2347900A (en) 2000-07-12
HUP0203054A2 (hu) 2003-01-28
CN1285588C (zh) 2006-11-22
PE20001516A1 (es) 2001-01-06

Similar Documents

Publication Publication Date Title
BR9916328A (pt) Inibidores de transferase de farnesila
BR9907429A (pt) Composto de hidrazida, processo para sua preparação e composições farmacêuticas contendo os mesmos
DK0677039T3 (da) Cyclobutanderivater som squalen-syntetase- og protein-farnesyltransferaseinhibitorer
BR9806752A (pt) Ftalazinonas.
ATE423557T1 (de) Carbocyclische kaliumkanalhemmer
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
CY1105912T1 (el) Αναστολεις συγκολλησης κυτταρου
BR9706792A (pt) Derivado de tiazol
BR9812564A (pt) Amidas de ácido acilsulfamoilbenzóico, agentes protetores de plantas úteis contendo as mesmas e processos para a sua preparação
BR9911783A (pt) Compostos cìclicos substituìdos, processo para sua preparação e composições farmacêuticas que os contêm
ATE400274T1 (de) Hemmstoffe der akt aktivität
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
BR9714787A (pt) Compostos de 4- fenilpiperidina e processo para sua preparação
BR0315143A (pt) Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto
BR9807132A (pt) Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2
BR0110745A (pt) Compostos de piperazinadiona
ATE290382T1 (de) Heterozyklische kalium-kanal inhibitoren
BR9909781A (pt) Composto de formula (i), processo para sua preparação, composição farmacêutica compreendendo dito composto, seu uso e método.
DE69905476T2 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
DE69819525D1 (de) Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol
BR9805031A (pt) Compostos de naftaleno, processo para sua preparação e composições farmacêuticas contendo os mesmos.
BR9914355A (pt) Derivados de mononitrato de isosorbida e sua utilização como agentes vasodilatadores com tolerância reduzida
BR9713207A (pt) Derivados de 3-mercaptoacetilamino-1,5-substituìdo-2-oxo-azepan uteis como inibidores de metaloproteinase de matriz
BR9916314A (pt) Inibidores tricìclicos da proteìna farnesil transferase
BR9909237A (pt) Inibidores de farnesil-proteìna transferase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.